GlassScriptPhysician profile
Amy Hayden Ray
NPI 1003801986
$922.68
in general payments reported to CMS, 2019-2025
17 companies · $125 in 2025
The $125 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $133 · 2021: $79.73 · 2022: $166 · 2023: $104 · 2024: $205 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $209.66 | 2019-2024 | |
| Corium, LLC | $159.69 | 2021-2025 | Azstarys |
| Tris Pharma INC | $88.37 | 2019-2024 | Dyanavel Xr |
| Pfizer INC. | $80.22 | 2019-2025 | |
| Sanofi Pasteur INC. | $59.49 | 2019-2025 | |
| Verrica Pharmaceuticals INC. | $49.27 | 2024-2025 | Ycanth |
| Takeda Pharmaceuticals U.S.A., INC. | $47.45 | 2020-2021 | |
| Sobi, INC | $39.93 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $30.84 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $27.49 | 2021-2023 | Qelbree |
| Shire North American Group INC | $22.11 | 2019 | |
| Biomarin Pharmaceutical INC. | $20.51 | 2024 | Voxzogo 1.2mg |
| Qiagen, LLC | $19.39 | 2022 | |
| Seqirus USA INC | $18.55 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.74 | 2024 | Crysvita |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $16.38 | 2024 | |
| Ironwood Pharmaceuticals, INC | $15.59 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.